Selective JAK Inhibitors for Rheumatoid Arthritis

  • ID: 2849594
  • Report
  • Region: Global
  • 40 Pages
  • LifeTech Research
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Astellas
  • Eli Lilly
  • Galapagos
  • Incyte Corporation
  • Johnson & Johnson
  • MORE
The role of Janus kinases (JAKs) in mediating inflammation and autoimmunity suggested that they would be appropriate targets for intervention in rheumatoid arthritis (RA). JAKs are a family of intracellular, non-receptor protein tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Pfizer's tofacitinib (Xeljanz) was launched in 2012 for patients with moderate to severe RA. The drug is an oral JAK inhibitor with specificity for JAK1 and JAK2 but with residual activity for JAK2 – leading to some significant safety concerns.

Safety risks associated with tofacitinib are related to its activity as an immunosuppressant, effects on hematopoietic blood cells, and modulation of cholesterol levels – all important in managing RA. So far tofacitinib's revenues have disappointed.

Selective JAK inhibitors, all oral, in current development for RA and described in the report are:
- Baricitinib (Incyte Corporation, Eli Lilly)
- INCB39110 (Incyte Corporation)
- ASP-015K (Astellas, Johnson & Johnson)
- GLPG0634 (Galapagos)
- ABT-494 (AbbVie)
- VX-509 (Vertex)
A next generation oral specific JAK1 or JAK3 inhibitor, with superior efficacy and/or better safety profile than tofacitinib, will have a better chance of capturing significant market share in the second-line >$3 billion TNF inhibitor market.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Astellas
  • Eli Lilly
  • Galapagos
  • Incyte Corporation
  • Johnson & Johnson
  • MORE
Rheumatoid Arthritis
- Disease mechanisms – Role of JAKs in Autoimmunity
- Current treatments

Tofacitinib (Xeljanz)
- Pharmacology
- Clinical Efficacy
- Clinical Safety
- Disappointing sales thus far

Second generation JAK inhibitors
- Baricitinib (Incyte Corporation and Eli Lilly)
- INCB39110 (Incyte Corporation)
- ASP-015K (Astellas and JNJ)
- GLPG0634 (Galapagos and AbbVie)
- ABT-494 (AbbVie)
- VX-509 (Vertex)

Clinical and regulatory Discussion

Regulatory Issues

Market opportunity
- Comparative Efficacy for JAK Inhibitors

Summary opinion
- How does the Xeljanz experience inform the development of second generation JAK inhibitors?
- How will the second generation JAK inhibitors be differentiated?
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- AbbVie
- Astellas
- Eli Lilly
- Galapagos
- Incyte Corporation
- Johnson & Johnson
- Pfizer
- Vertex
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll